English Polski
Vol 17, No 1 (2022)
Original paper
Published online: 2022-01-14

open access

Page views 5120
Article views/downloads 321
Get Citation

Connect on Social Media

Connect on Social Media

Prevalence and control of arterial hypertension in Mazovian men and women enrolled in the POLASPIRE study

Małgorzata Setny1, Radosław Piątkowski2, Arkadiusz Rak3, Agnieszka Krzykwa1, Piotr Kułak4, Piotr Jankowski56, Dariusz Kosior47
Folia Cardiologica 2022;17(1):11-19.


Introduction. Arterial hypertension (AH) is one of the major modifiable risk factors for cardiovascular disease, which increases cardiovascular morbidity and mortality. The aim of this study was to evaluate AH prevalence and treatment control in men and women with coronary artery disease. Material and methods. The study included patients enrolled in the POLASPIRE trial in the Mazovian region. Definitions of risk factors and therapeutic targets were based on the 2016 European Society of Cardiology guidelines for cardiovascular prevention. Results. AH was diagnosed in 88% of women and 81% of men (p = 0.56). Among AH patients, women were older than men (p < 0.001). There were no statistically significant gender-related differences in the prevalence of diabetes mellitus (p = 1.00), dyslipidemia (p = 0.42), and obesity (p = 0.47). Women were more likely to have a history of stroke (p < 0.001), reduced glomerular filtration rate values (p < 0.001), elevated low-density lipoprotein cholesterol (p = 0.029), and non-high-density lipoprotein cholesterol levels (p = 0.022) as well as echocardiographic features of left ventricular diastolic dysfunction (p = 0.006). 51% of women and 50% of men (p = 1.00) did not achieve blood pressure targets. There were no significant differences between groups regarding pharmacotherapy for AH. Conclusions. The prevalence of AH in patients with coronary artery disease is high. A significant percentage of men and women do not achieve recommended blood pressure values. There is a need to improve the effectiveness of antihypertensive treatment.

Article available in PDF format

View PDF Download PDF file


  1. Zdrojewski T, Rutkowski M, Bandosz P, et al. Ocena rozpowszechnienia i kontroli czynników ryzyka chorób serca i naczyń w Polsce — badania NATPOL 1997, 2002, 2011. Med Prakt. 2015: 57–64.
  2. Niklas A, Flotyńska A, Puch-Walczak A, et al. WOBASZ II investigators. Prevalence, awareness, treatment and control of hypertension in the adult Polish population - Multi-center National Population Health Examination Surveys - WOBASZ studies. Arch Med Sci. 2018; 14(5): 951–961.
  3. Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension (August 5, 2021).
  4. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017; 317(2): 165–182.
  5. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014; 383(9932): 1899–1911.
  6. Webster AC, Nagler E, Morton R, et al. Chronic kidney disease. Lancet. 2017; 389(10075): 1238–1252.
  7. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957–967.
  8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016; 34(4): 613–622.
  9. Jankowski P, Kosior DA, Sowa P, et al. Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiol J. 2020; 27(5): 533–540.
  10. Kotseva K, De Backer G, De Bacquer D, et al. EUROASPIRE Investigators*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824–835.
  11. Nagueh SF, Smiseth OA, Appleton CP, et al. Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4): 277–314.
  12. Lang RM, Badano L, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear J — Cardiovasc Imaging. 2015; 16(3): 233–271.
  13. Piepoli MF, Hoes A, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016; 37(29): 2315–2381.
  14. Jankowski P, Kawecka-Jaszcz K, Bilo G, et al. Determinants of poor hypertension management in patients with ischaemic heart disease. Blood Press. 2005; 14(5): 284–292.
  15. Zdrojewski T, Wizner B, Więcek A, et al. Prevalence, awareness, and control of hypertension in elderly and very elderly in Poland: results of a cross-sectional representative survey. J Hypertens. 2016; 34(3): 532–8; discussion 538.
  16. Lonn EM, Bosch J, López-Jaramillo P, et al. HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374(21): 2009–2020.
  17. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014; 32(12): 2285–2295.
  18. Williamson JD, Supiano M, Applegate W, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. JAMA. 2016; 315(24): 2673.
  19. Brunström M, Carlberg Bo. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018; 178(1): 28–36.
  20. Böhm M, Schumacher H, Teo K, et al. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Eur Heart J. 2018; 39(33): 3105–3114.
  21. Williams B, Mancia G, Spiering W, et al. List of authors/Task Force members:. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018; 36(12): 2284–2309.
  22. Nagueh SF. Left ventricular diastolic function: understanding pathophysiology, diagnosis, and prognosis with echocardiography. JACC Cardiovasc Imaging. 2020; 13(1 Pt 2): 228–244.
  23. Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin e in patients at high risk of cardiovascular events. Can J Cardiol. 1996; 12: 127–137.
  24. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287): 1033–1041.
  25. Borghi C, Cicero AFG, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag. 2008; 4(3): 665–671.
  26. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311): 995–1003.
  27. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens. 2006; 24(11): 2163–2168.
  28. Mancia G, Unger T, Zanchetti A. Introduction: Reducing cardiovascular risk: ONTARGET — a new standard in cardiovascular protection. J Hypertens Suppl. 2009; 27(5): S1.
  29. Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017; 389(10085): 2226–2237.
  30. Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137.